Delivering adaptive radiotherapy to the bladder during radical treatment

Journal of Radiotherapy in Practice

Volumn 12, Issue 2, 2013, Pages 195-202

  Arthur, Claire ^a   Livsey, Jac ^a   Choudhury, Ananya ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adaptive; Bladder; Imaging; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER;

ADAPTIVE RADIOTHERAPY; BLADDER CANCER; BLADDER CAPACITY; CANCER PATIENT; CANCER RADIOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY; HEALTH CARE DELIVERY; HUMAN; IMAGE ANALYSIS; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; PARTIAL BLADDER RADIOTHERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOLOGICAL PROCEDURES; REVIEW; TREATMENT PLANNING;

EID: 84879941469     PISSN: 14603969     EISSN: 14671131     Source Type: Journal    
DOI: 10.1017/S1460396912000118     Document Type: Review

References (29)

1. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008; 70:456-463.
2. Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, Van der Voet J, Collins CD, Khoo VS, Read GR. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:197-207.
3. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial. J Clin Oncol 2011; 29: 2171-2177.
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and metaanalysis of individual patient data. Eur Urol 2005; 48:202-206.
5. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010; 28:4912-4918.
6. James ND, Hussain SA, Hall E et al. Results of a phase III randomised trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 2010; 28:15s (suppl; abstr 4517).
7. Pos F, Remeijer P. Adaptive management of bladder cancer radiotherapy. Semin Radiat Oncol 2010; 20:116-120.
8. Sterzing F, Engenhart-Cabillic R, Flentje M, Debus J. Image-guided radiotherapy: a new dimension in radiation oncology. Dtsch Arztebl Int 2011; 108:274-280.
9. Logue J, McBain CA. Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery. Clin Oncol (R Coll Radiol) 2005; 17:508-513.
10. Button MR, Staffurth JN. Clinical application of image-guided radiotherapy in bladder and prostate cancer. Clin Oncol (R Coll Radiol) 2010; 22:698-706.
11. Burridge N, Amer A, Marchant T, Sykes J, Stratford J, Henry A, McBain C, Price P, Moore C. Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction. Int J Radiat Oncol Biol Phys 2006; 66:892-897.
12. Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol 2007; 25:76-84.
13. Muren LP, Redpath AT, Lord H, McLaren D. Image-guided radiotherapy of bladder cancer: bladder volume variation and its relation to margins. Radiother Oncol 2007; 84:307-313.
14. Murthy V, Master Z, Adurkar P, Mallick I, Mahantshetty U, Bakshi G, Tongaonkar H, Shrivastava S. 'Plan of the day' adaptive radiotherapy for bladder cancer using helical tomotherapy. Radiother Oncol 2011; 99:55-60.
15. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010; 76:S116-S122.
16. McBain CA, Khoo VS, Buckley DL, Sykes JS, Green MM, Cowan RA, Hutchinson CE, Moore CJ, Price PM. Assessment of bladder motion for clinical radiotherapy practice using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 75:664-671.
17. Turner SL, Swindell R, Bowl N, Marrs J, Brookes B, Read G, Cowan RA. Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int J Radiat Oncol Biol Phys 1997; 39:355-360.
18. McBain CA, Henry AM, Sykes J, Amer A, Marchant T, Moore CM, Davies J, Stratford J, McCarthy C, Porritt B, Williams P, Khoo VS, Price P. X-ray volumetric imaging in image-guided radiotherapy: the new standard in on-treatment imaging. Int J Radiat Oncol Biol Phys 2006; 64:625-634.
19. Ost P, De Gersem W, De Potter B, Fonteyne V, De Neve W, De Meerleer G. A comparison of the acute toxicity profile between two-dimensional and three-dimensional image-guided radiotherapy for postoperative prostate cancer. Clin Oncol (R Coll Radiol) 2011; 23:344-349.
20. Faroudi F, Wong J, Kron T et al. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int. J. Radiation Oncol Biol. Phys 2010; doi:10.1016/j.ijrobp.2010.06.061.
21. Varadhan R, Hui SK, Way S et al. Assessing prostate, bladder and rectal doses during image guided radiation therapy-need for plan adaptation? Journal of Applied Clinical Medical Physics 2009; 10:56-74.
22. Foroudi F, Wong J, Haworth A, Baille A, McAlpine J, Rolfo A, Kron T, Roxby P, Paneghel A, Williams S, Duchesne G, Tai KH. Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography. J Med Imaging Radiat Oncol 2009; 53:226-233.
23. Lagendijk JJ, Raaymakers BW, Raaijmakers AJ, Overweg J, Brown KJ, Kerkhof EM, Van der Put RW, Hårdemark B, van Vulpen M, Van der Heide UA. MRI/linac integration. Radiother Oncol 2008; 86:25-29.
24. Hulshof MC, van Andel G, Bel A, Gangel P, van De Kamer JB. Intravesical markers for delineation of target volume during external focal irradiation of bladder carcinomas. Radiother Oncol 2007; 84:49-51.
25. Mangar S, Thompson A, Miles E, Huddart R, Horwich A, Khoo V. A feasibility study of using gold seeds as fiducial markers for bladder localization during radical radiotherapy. Br J Radiol 2007; 80:279-283.
26. Pos F, Bex A, Dees-Ribbers HM, Betgen A, van Herk M, Remeijer P. Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancer. Radiother Oncol 2009; 93:364-367.
27. Parliament MB, Murray D. Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol 2010; 20:232-240.
28. West CM, McKay MJ, Hölscher T, Baumann M, Stratford IJ, Bristow RG, Iwakawa M, Imai T, Zingde SM, Anscher MS, Bourhis J, Begg AC, Haustermans K, Bentzen SM, Hendry JH. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 2005; 62:1264-1273.
29. Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, Kiltie AE. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010; 70:7017-7026.